Table 2.
Cellular event | Pathway(s) implicated | Potential personalized treatments |
---|---|---|
Migration across BBB | cathepsin S | Inhibitors in development |
miR-181C | None to date | |
miR-105 | None to date | |
Survival in CNS microenvironment | mTOR | Everolimus, temsirolimus |
CDK | Palbociclib, others in development | |
VEGF | Bevacizumab | |
EGFR | Erlotinib | |
Establishment of radioresistance | Chk1 | Inhibitors in development |
c-Met | Cabozantinib |